Patients’ preferences for adjuvant chemotherapy in early-stage breast cancer: is treatment worthwhile?
| Autor: | Anne M. Stiggelbout, Job Kievit, H.-J. van Slooten, M. Nooij, J.C.J.M. de Haes, E Maartense, I M E Overpelt, Sylvia J. T. Jansen |
|---|---|
| Přispěvatelé: | Other departments |
| Rok vydání: | 2001 |
| Předmět: |
Adult
Cancer Research medicine.medical_specialty Adjuvant chemotherapy medicine.medical_treatment Decision Making Mammary gland Breast Neoplasms chemotherapy breast cancer Breast cancer Patient satisfaction Internal medicine medicine Humans Stage (cooking) preferences Aged Demography Physician-Patient Relations Chemotherapy business.industry Data Collection shared decision-making cognitive dissonance reduction Regular Article Middle Aged medicine.disease Surgery medicine.anatomical_structure Oncology Chemotherapy Adjuvant Patient Satisfaction Female Positive attitude business Attitude to Health Chemotherapy group |
| Zdroj: | British journal of cancer, 84(12), 1577-1585. Nature Publishing Group British Journal of Cancer |
| ISSN: | 1532-1827 0007-0920 |
| DOI: | 10.1054/bjoc.2001.1836 |
| Popis: | When making decisions about adjuvant chemotherapy for early-stage breast cancer, costs and benefits of treatment should be carefully weighed. In this process, patients' preferences are of major importance. The objectives of the present study were: (1) to determine the minimum benefits that patients need to find chemotherapy acceptable, and (2) to explore potential preference determinants, namely: positive experience of the treatment, reconciliation with the treatment decision, and demographic variables. Preferences were elicited from patients scheduled for adjuvant chemotherapy (chemotherapy group: n = 38) before (T 1), during (T 2), and 1 month after chemotherapy (T 3), and were compared to responses from patients not scheduled for chemotherapy (no-chemotherapy group: n = 38). The patients were asked, for a hypothetical situation, to indicate the minimum benefit (in terms of improved 5-year disease-free survival) to find adjuvant chemotherapy acceptable. In the chemotherapy group, the median benefit was 1% at all 3 measurement points. In the no-chemotherapy group the attitude towards chemotherapy became more negative over time, although not statistically significantly so (T 1: 12%, T 2: 15%, T 3: 15%;P = 0.10). At all measurement points, the patients in the chemotherapy group indicated that they would accept chemotherapy for significantly (P< 0.01) less benefit than the patients in the no-chemotherapy group. Of the demographic variables, age was related to preferences, but only at T 2 and only in the no-chemotherapy group. The more positive attitude towards chemotherapy and the stability of preferences in the chemotherapy group indicated that reconciliation with the treatment decision was a more important determinant of patients' preferences than positive experience of the treatment. © 2001 Cancer Research Campaign http://www.bjcancer.com |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|